Biểu đồ giá cổ phiếu KLRS
KLRS Dự đoán giá cổ phiếu
Kalaris Therapeutics Inc
$4.73
-6.88%
$-0.34
Khi đóng cửa: May 11, 16:00:00 GMT-4
$4.82
1.9%
$0.08
Phiên sau giờ: May 11, 20:00:00 GMT-4
Quay lại
Kalaris Therapeutics Inc (KLRS) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$5.08
Giá mở cửa
$5.02
Phạm vi ngày
$4.69 - $5.05
Phạm vi 52 tuần
$2.14 - $11.88
Khối lượng
155.0K
Khối lượng trung bình
74.5K
Tỷ suất cổ tức
--
EPS (TTM)
-4.27
Vốn hóa thị trường
$110.5M
KLRS là gì?
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
